Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Alemtuzumab and Rituximab for Refractory Autoimmune Cytopenias
NCT00749112Phase 3Completed
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Aug 2008
- Primary completion
- Aug 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of alemtuzumab, rituximab in immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Started Aug 2008; status: completed.
02
Drugs
alemtuzumabrituximab
03
Conditions
immune thrombocytopenia (ITP)autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT00749112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00749112.